Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Fenofibrate/Pitavastatin FDC vs Coadministration in Healthy Males
NCT02250976Phase 1Completed
- Sponsor
- Hanlim Pharm
- Start
- Sep 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fenofibrate and pitavastatin in mixed dyslipidemia (2 arms), sponsored by Hanlim Pharm. Primary endpoints: Area Under the Curve to the last measurable concentration at 96 hours and Maximum Plasma Concentration at 96 hours. Started Sep 2014; status: completed.
02
Drugs
fenofibratepitavastatin
03
Conditions
mixed dyslipidemia
Beyond the preview
Go deeper on NCT02250976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02250976.